Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tarlatamab with carboplatin, etoposide, and atezolizumab for EGFR-mutant adenocarcinoma transformed to small cell lung cancer
KCT0010234Phase 2Recruiting
- Sponsor
- Amgen
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab, atezolizumab, carboplatin, etoposide in small cell lung cancer (SCLC), sponsored by Amgen. Started May 2025; status: recruiting.
02
Drugs
tarlatamabatezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0010234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010234.